In DNA repair, the resection of double-strand breaks dictates the choice between homology-directed repair-which requires a 3′ overhang-and classical non-homologous end joining, which can join unresected ends 1,2 . BRCA1-mutant cancers show minimal resection of double-strand breaks, which renders them deficient in homology-directed repair and sensitive to inhibitors of poly(ADPribose) polymerase 1 (PARP1) 3-8 . When BRCA1 is absent, the resection of double-strand breaks is thought to be prevented by 53BP1, RIF1 and the REV7-SHLD1-SHLD2-SHLD3 (shieldin) complex, and loss of these factors diminishes sensitivity to PARP1 inhibitors 4,6-9 . Here we address the mechanism by which 53BP1-RIF1-shieldin regulates the generation of recombinogenic 3′ overhangs. We report that CTC1-STN1-TEN1 (CST) 10 , a complex similar to replication protein A that functions as an accessory factor of polymerase-α (Polα)-primase 11 , is a downstream effector in the 53BP1 pathway. CST interacts with shieldin and localizes with Polα to sites of DNA damage in a 53BP1-and shieldin-dependent manner. As with loss of 53BP1, RIF1 or shieldin, the depletion of CST leads to increased resection. In BRCA1-deficient cells, CST blocks RAD51 loading and promotes the efficacy of PARP1 inhibitors. In addition, Polα inhibition diminishes the effect of PARP1 inhibitors. These data suggest that CST-Polα-mediated fill-in helps to control the repair of double-strand breaks by 53BP1, RIF1 and shieldin.
resection at telomeres when TPP1 was deleted from REV7-deficient cells ( Fig. 1b-d , Extended Data Fig. 2 ). Furthermore, STN1 knockdown had no effect on telomere hyper-resection when either 53BP1 or RIF1 were absent, or when cells contained a form of 53BP1 that does not recruit RIF1 23 (Extended Data Fig. 3 ). These data suggest that CST acts in a 53BP1-, RIF1-and shieldin-dependent manner to limit the formation of single-stranded DNA at dysfunctional telomeres.
To determine whether CST also counteracted resection at sites of ATM signalling, we used conditional deletion of Trf2 (Fig. 1e ). Telomeres that lack TRF2 undergo fusion mediated by classical nonhomologous end joining [24] [25] [26] . In cells deficient in DNA ligase IV (LIG4), in which such telomere fusions are prevented 26 , telomeres that lack TRF2 undergo 5′-end resection that is exacerbated by loss of 53BP1 or RIF1 8, 19 (Fig. 1e) . Similarly, the 5′-end resection was increased by REV7 or SHLD2 deficiency ( Fig. 1f -h, Extended Data Fig. 4 ). When STN1 was depleted from cells that lack TRF2, resection at telomeres was significantly increased ( Fig. 1f -h) and this effect was epistatic with REV7 ( Fig. 1f-h) . Thus, CST counteracts resection in a shieldindependent manner in the context of ATM signalling.
We next determined whether CST localized to damaged telomeres in a 53BP1-and shieldin-dependent manner. Myc-tagged CTC1 was detectable at telomeres with functional shelterin, whereas in cells that are deficient in POT1B-which show extended telomeric 3′ overhangs but no DNA damage signalling 27 -the localization of CTC1 at telomeres was minimal ( Fig. 2a, b ). When ATR was activated by deletion of Tpp1 (Fig. 2a, right) , CTC1 was again detectable at telomeres ( Fig. 2a, b ) despite the absence of POT1B. The recruitment of CTC1 to dysfunctional telomeres depended on ATR signalling, 53BP1 and shieldin ( Fig. 2b, c) . Similarly, Cre-mediated deletion of the single human POT1 protein from conditional POT1-knockout HT1080 cells 28 led to telomeric accumulation of STN1 that required ATR kinase ( Fig. 2d-f ). Thus, CST localizes to damaged telomeres in a shieldin-dependent manner.
Co-immunoprecipitation experiments showed that shieldin components could associate with CST ( Fig. 2g, Extended Data Fig. 5a ). In a yeast two-hybrid assay, CTC1 robustly interacted with SHLD1 and STN1 interacted with SHLD3 ( Fig. 2h, Extended Data Fig. 5b ). Weaker interactions were detectable between TEN1 and SHLD3; STN1 and SHLD1, SHLD2 or REV7; and CTC1 and REV7. Thus, shieldin binds CST through multiple direct interactions.
In human cells, STN1 co-localized with 53BP1 at DSBs induced by ionizing radiation (Fig. 3a, b ) in a manner dependent on shieldin (Fig. 3b ). Furthermore, STN1 was detectable at DSBs induced by FOKI in U2OS cells. This localization was diminished upon inhibition of ATM and ATR signalling, and required 53BP1 and shieldin ( Fig. 3c -e, Extended Data Fig. 6a ), which indicates that CST is recruited to sites of DNA damage by shieldin.
Because CST is associated with Polα-primase, we examined the localization of Polα at DSBs. Because Polα forms numerous S-phase foci (Extended Data Fig. 6b ), we examined cells arrested in G2 (Fig. 3f 
Tpp1 Extended Data Fig. 6c ). In cells that expressed HA-tagged STN1, Polα co-localized with STN1 at DSBs induced by FOKI ( Fig. 3f , Extended Data Fig. 6c ). The localization of Polα to DSBs was diminished upon inhibition of ATM and ATR signalling, and required 53BP1 and shieldin ( Fig. 3f , Extended Data Fig. 6d ), which demonstrates that Polα and CST require the same factors for their localization to DSBs. Depletion of STN1 increased the percentage of cells that contained replication protein A (RPA) foci after exposure to ionizing radiation ( Fig. 3g, i) , increased the signal intensity of the RPA foci ( Fig. 3h ) and increased the overall RPA signal intensity per nucleus (Extended Data Fig. 7 ). Furthermore, deletion of CTC1 from a human HCT116 cell line 21 led to an increase in the phosphorylation of RPA upon irradiation ( Fig. 3j ) and CST depletion increased phosphorylation of RPA in irradiated MEFs (Fig. 3k ). In cells that lack BRCA1, depletion of CST also increased the percentage of cells with RAD51 foci induced by ionizing radiation (Fig. 3l, m) , which suggests that this depletion restores homology-directed repair. Conversely, on the basis of an assay for the fusion of telomeres that lack TRF2 26 , it appears that the depletion of CST diminishes classical non-homologous end joining ( Fig. 3n, o) .
BRCA1-deficient cells become resistant to treatment with PARP1 inhibitors (PARPi) when 53BP1, RIF1 or shieldin are absent [3] [4] [5] [6] [7] [8] [9] .
Similarly, STN1 or CTC1 depletion from Brca1 f/f MEFs reduced the lethality of PARPi in BRCA1-deficient cells ( Fig. 4a , b, Extended Data Fig. 8a-f ). By contrast, in Brca1 f/f subclones that lack 53BP1 or REV7, depletion of CTC1 or STN1 did not affect resistance to PARPi (Fig. 4c , Extended Data Fig. 8c-f ). Furthermore, in BRCA1-deficient cells, CST depletion reduced the radial chromosomes induced by PARPi ( Fig. 4d , e) and this effect was epistatic with 53BP1 and REV7 ( Fig. 4e ). These data are consistent with CST acting together with 53BP1 and shieldin to minimize formation of single-stranded DNA at DSBs.
To examine the consequences of Polα inhibition in PARPi-treated BRCA1-deficient cells without confounding S-phase effects, cells were arrested in G2 before addition of Polα inhibitors ( Fig. 4f ). Cells that experienced Polα inhibition in G2 showed reduced formation of radial chromosomes ( Fig. 4f , Extended Data Fig. 8g ). BrdU incorporation experiments confirmed that the mitotic cells we collected had passed through S phase during treatment with PARPi (Extended Data Fig. 8h -j). The effect of Polα inhibition with 10 μm CD437 was not exacerbated by depletion of CST ( Fig. 4f ). Collectively, these data are consistent with CST and Polα acting to limit the formation of recombinogenic 3′ overhangs at DSBs in BRCA1-deficient cells (Fig. 4g ).
Our data suggest a sophisticated mechanism by which 53BP1 and shieldin act together with CST and Polα to fill in resected DSBs. At telomeres, the POT1-TPP1 heterodimer recruits CST-Polα-primase to fill in part of the 3′ overhang formed after telomere end resection ( Fig. 4g ). We propose that at sites of DNA damage, shieldin recruits CST-Polα-primase for the purpose of filling in resected DSBs. In both settings, CST is tethered, allowing CST to engage single-stranded DNA despite its modest affinity for this substrate 29 and enabling regulation of the fill-in reaction through recruitment. Recent data have shown that 53BP1 represses mutagenic single-strand annealing, possibly by preventing excessive resection 30 . Our findings regarding CST-Polα could explain this observation. At telomeres, partial fill-in by CST-Polα counteracts hyper-resection but leaves a 3′ overhang that can form a t-loop, a process similar to the initiation of homology-directed repair 12, 13 . At DSBs, CST-Polα could similarly counteract hyper-resection-and thus single-strand annealing-and generate a 3′ overhang that is sufficient for homology-directed repair. In BRCA1-deficient cells, this fill-in reaction, together with the persistence of CST-shieldin at the DSBs, could block homology-directed repair and result in lethal mis-repair.
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Stn1 Ctrl U2OS cells containing a LacO array and a tamoxifen-and Shield1-regulated mCherry-FOKI-LacI fusion were used as described 34 . Cells were collected 4 h after induction of FOKI by addition of 0.1 μM Shield1 and 10 μg/ml 4-OHT. Human CTC1 f/f HCT116 cells 21 were cultured in McCoy's 5A supplemented with 10% FCS, non-essential amino acids, l-glutamine and penicillin-streptomycin as above. CTC1 gene deletion was induced with 0.5 μM 4-OHT for 5 h. Gene deletion was confirmed by western blot using anti-CTC1 antibody (MABE1103, Millipore).
Mouse CTC1 tagged at the N terminus with a 6×Myc tag was delivered by retroviral transduction using pLPC or pWZL retroviral vectors. Human STN1 tagged at the N terminus with a 6×HA tag was delivered using the pLPC vector. Myc-tagged RPA32 35 , and 53BP1 wild type and 53BP1∆Rif1 23 constructs were as described. Retroviral gene delivery was performed as described 16 .
RNA depletion with shRNAs in pLKO.1 (Open Biosystems) was performed using the following shRNA target sites: shStn1 1: 5′-GATCCTGTGTTTCTAGCCTTT-3′ (TRCN0000180836, Sigma); shStn1 2: 5′-GCTGTCATCAGCGTGAAAGAA-3′ (TRCN0000184261, Sigma); shCtc1: 5′-CGGCAGATCACAGCATGATAA-3′; shAtr 1: 5′-CTGTGGTTGTATCTGTTCAAT-3′ (TRCN0000039613, Sigma); shAtr 2: 5′-GATGAACACATGGGATATTTA-3′ (TRCN0000196538, Sigma). Lentiviral constructs were co-transfected with packaging vectors into 293T cells and cells infected with the viral supernatant were selected in puromycin as described 16 .
Drug treatments were as follows. ATR inhibition: 2.5 μM ETP-46464 (Sigma), 24 h; PARP1 inhibition: 0.1-10 μM Olaparib (Selleck Chemicals), 24 h; G2 arrest: 9 μM RO-3306 (Sigma), 12 h; polymerase α inhibition: 2.5 or 10 μM CD437 (Sigma) or 2 μM Aphidicolin, 4 h. ATM and ATR inhibition: 10 μM KU55933 (Selleck Chemical) with ATR inhibition as above for 4 h during induction of FOKI nuclease. CRISPR-Cas9 gene disruption. Clonal cell lines with disruption of mouse 53BP1 were generated using Cas9 vector (Addgene) and sgRNA (sg53bp1 (2), 5′-GAGAATCTTCTATTATC-(PAM)-3′; sg53bp1 (3), 5′-GCATCTGCA GATTAGGA-(PAM)-3′ 20 ) delivered by nucleofection (Amaxa Kit R, Lonza). Clones were screened by immunoblotting and bi-allelic gene disruption was verified by Sanger sequencing of Topo-cloned PCR products of the relevant locus (sequences available on request). Clonal cell lines with mouse Rev7 gene disruption were isolated similarly using the following sgRNAs: sgRev7(2), 5′-GTGTCCCCACCACAGTGG-(PAM)-3′; and sgRev7(3), 5′-GCCGGTTC AGGTGAGCCC-(PAM)-3′) (disrupted gene sequences available on request). Oligonucleotides were purchased from Sigma-Aldrich and cloned into the AflIIdigested gRNA expression vector (Addgene) by Gibson Assembly (New England Biolabs). For isolation of populations with CRISPR-Cas9 disruption of mouse Shld2 (FAM35A), 293T cells were transfected with lentiCrispr-v2-Shld2-sgRNA (5′-ATCAGTCAGATCCCTGCGTT-(PAM)-3′) or the vector control. The lentiviral supernatant was used for infection of Tpp1 f/f or Trf2 f/f Lig4 −/− MEFs; infections were done six times at 6-12 h intervals. Infected cells were then selected in puromycin for 3-5 days before Cre infection.
FOKI-LacI U2OS cells were infected with the 6×-HA-tagged human STN1 retrovirus and selected in puromycin. Subsequently, cells were subjected to lentiviral infection with lentiCrispr-v2 carrying sgRNA for human 53BP1, SHLD2 or REV7 and selected in blasticidin for 3 days. Target sequences for gene disruption are as follows: human 53BP1 sgRNA1 (5′-CAGAATCATCCTCTAGAACC-
sgRNA2 (5′-TTTGAGCTAAAAAAGCAACC-(PAM)-3′), REV7 sgRNA1 (5′-CCT CAACTTTGGCCAAGGTA-(PAM)-3′), REV7 sgRNA2 (5′-TATACTGATTC AGCTCCGGG-(PAM)-3′). For each gene the two sgRNAs were either used individually or together. In-gel analysis of single-stranded telomeric DNA. Mouse telomeric overhang and telomeric restriction fragment patterns were analysed 96-120 h after Cre treatment by in-gel hybridization with a γ-32 P-ATP end-labelled (AACCCT) 4 probe, as previously described 26 . Treatment with E. coli exonuclease I before MboI digestion was used to verify the 3′ terminal position of the single-stranded DNA as previously described 20 . ImageQuant software was used to quantify the single-stranded telomere overhang signals and the signal from total telomeric DNA in the same lane in the denatured gel. In each experiment, this ratio was set to 1 for lanes not treated with Cre or shRNA and the ratios for the treated samples are given relative to this control. Flow cytometry. FACS was performed as previously described 36 with gating. Immunoblotting. Immunoblotting was performed as described 16 with the following antibodies: 53BP1 (175933, Abcam; NB100-304, Novus Biological); ATR (sc-1887, Santa Cruz Biotechnology); BRCA1 (MAB22101, R+D systems); CHK1 (sc-8408, Santa Cruz Biotechnology); CHK1-S345-P (#2341S; Cell Signaling Technology); CHK2 (BD 611570, BD Biosciences); Flag-tag (M2, Sigma; F1804, Sigma); γ-tubulin (GTU488, Sigma); MAD2L2/REV7 (ab180579, Abcam); Myc-tag (9B11, Cell Signaling Technology); OBFC1/STN1 (E10-376450, Santa Cruz Biotechnology); Tagged TEN1 was not detectable by immunoblotting of transfected 293T cells.
For detection of RPA phosphorylation, conditional CTC1 HCT116 cells or MEFs were irradiated and collected 3 h later. Cells were washed in PBS, and then collected by scraping in Laemmli sample buffer, boiling for 5 min and shearing through a syringe. Proteins were separated by SDS-PAGE on 8-16% Tris-glycine gradient gels (Invitrogen), and transferred to nitrocellulose overnight. Immunoblotting for pRPA followed standard protocols with blocking in 5% milk/TBST and the pRPA antibody (S4/S8; Bethyl) diluted 1:1,000 in 1% milk/TBST. Immunoprecipitation. Immunoprecipitation was carried out as described 16 . The following plasmids were used: pLPC-flag-POT1a and pLPC-flag-POT1b 27 ; pLPC-myc-mouse Ctc1, pLPC-myc-mouse Stn1 and pLPC-myc-mouse Ten1 16 ; pLPC-myc-human Ctc1, pLPC-myc-human Stn1, pLPC-myc-human Ten1, pCD-NA5-flag-human Shld1 (C20orf196) and pLPC-myc-hRev7, pLPC-flag-mouse Shld1 (orthologue of C20orf196). Human REV7, SHLD1, CTC1, STN1 and TEN1 ORFs were generated by PCR and mouse Shld1 was generated by RT-PCR. Co-transfection of Shld1 and Rev7 with CST in 293T cells was performed using calcium phosphate co-precipitation. Lysates were prepared in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10% glycerol and 0.1% NP-40, Complete protease inhibitor mix (Roche), and PhosSTOP phosphatase inhibitor mix (Roche) and 50 U benzonase. Yeast two-hybrid assays. For yeast two-hybrid analysis, full-length versions of human CST and shieldin components were cloned into the NdeI site of the pGBKT7 and pGADT7 vectors (Clontech). Plasmids in the indicated pairwise combinations were co-transformed into budding yeast strain PJ69-4A (MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4 gal80 LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ) and selected on synthetic complete drop-out medium lacking tryptophan and leucine. Protein interactions were tested by plating on the same medium but also lacking adenine. Immunofluorescence and IF-FISH. Previously published procedures were followed for immunofluorescence and IF-FISH 16 . Immunofluorescence for Myctagged RPA32 or CTC1 (mouse monoclonal, 9B11 or rabbit monoclonal, 71D10, Cell Signaling Technology), HA-tagged STN1 (3724, Cell Signaling Technology), endogenous Polα (sc-137021, Santa Cruz), and 53BP1 (612522, BD Biosciences) was carried out using the cytoskeleton extraction protocol 37 . Intensity measurements of RPA32-Myc immunofluorescence were performed in FIJI as follows: nuclei were identified using thresholding, segmented and identified as regions of interest. The average image background was then subtracted from the image, and the total raw pixel intensity within each area of interest in the channel of interest was calculated. RAD51 (70-001, Bioacademia), and γH2AX (05636, Millipore) were detected in cells fixed in 3% PFA, and foci showing co-localization of RAD51 with γH2AX were quantified. Immunofluorescence imaging was performed on a Zeiss Axioplan II microscope equipped with a Hamamatsu C4742-95 camera using Volocity software or on a DeltaVision (Applied Precision) equipped with a cooled charge-coupled device camera (DV Elite CMOS Camera), a PlanApo 60× 1.42 NA objective or 100× 1.40 NA objective (Olympus America), and SoftWoRx software. Telomere fusion assays. SV40LT-immortalized Trf2 f/f Rosa creER cells were infected with Stn1 shRNA (or the empty vector) and 24 h later Cre was induced for 24 h with 4-OHT. Cells were collected, counted (to rule out a proliferation defect) and processed for telomeric FISH on metaphases 72 h after Cre induction. This early time point was selected to avoid any effect of the Stn1 shRNA on proliferation, as Letter reSeArCH diminished proliferation reduces fusion frequencies. Telomere fusions were scored as previously described 26 . Survival assays and chromosome analysis. PARPi survival assays and analysis of misrejoined chromosomes were carried out as described 19 , except that for analysis of radial chromosomes, MEFs were incubated with 0.5 μM Olaparib (AZD2281) for 24 h before collection. For the survival assays, MEFs were seeded in 6-well plates in duplicate at 10, 50, 100, 500, 1,000, 5,000 or 10,000 cells per well. After 24 h, cells were treated with Olaparib at the indicated concentrations for 24 h. Cells were then provided with medium without Olaparib and incubated for one week with a medium change at day 4. Colonies were fixed and stained with 50% methanol, 2% methylene blue, rinsed with water and dried before counting. The survival percentage at each PARPi concentration compared to untreated cells was calculated using wells with 10-100 colonies. Two technical replicates at two cell concentrations were scored for each condition in three independent experiments. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper.
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Extended Data Fig. 2 | Hyper-resection at telomeres that lack TPP1 is counteracted by CST and shieldin. a, Immunoblots showing absence of REV7 and reduction of STN1 expression in the indicated Tpp1 f/f and Tpp1 f/f Rev7 −/− MEFs treated with either Ctc1 or Stn1 shRNA. Diminished STN1 expression is used as a proxy for the efficacy of the Ctc1 shRNA. Representative of two experiments. b, Quantitative analysis of telomeric overhangs, as in Fig. 1c . Representative of two experiments. c, Quantification of the effect of Ctc1 and Stn1 shRNA on resection at telomeres that lack TPP1, as in Fig. 1d . Data are obtained from two independent REV7-proficient and two independent REV7-deficient clones (light and dark shading). A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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All MEF cell lines were genotyped by Transnetyx Inc. using real time PCR with allele-specific probes and confirmed by western blot. The three human cell lines were verified based on the appropriate cell biological read-outs (Cre induced loss of Ctc1 or POT1 and induction of FOKI cuts).
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